<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-archivearticle1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4544847</article-id><article-id pub-id-type="pmid">26288277</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0133925</article-id><article-id pub-id-type="publisher-id">PONE-D-15-12403</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="0" pm="."><plain>Low Level Engraftment and Improvement following a Single Colonoscopic Administration of Fecal Microbiota to Patients with Ulcerative Colitis </plain></SENT>
</text></SecTag></article-title><alt-title alt-title-type="running-head">FMT for UC Engraftment</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Damman</surname><given-names>Christopher J.</given-names></name><xref ref-type="aff" rid="aff001">
<sup>1</sup>
</xref><xref rid="cor001" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Brittnacher</surname><given-names>Mitchell J.</given-names></name><xref ref-type="aff" rid="aff002">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Westerhoff</surname><given-names>Maria</given-names></name><xref ref-type="aff" rid="aff003">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Hayden</surname><given-names>Hillary S.</given-names></name><xref ref-type="aff" rid="aff002">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Radey</surname><given-names>Matthew</given-names></name><xref ref-type="aff" rid="aff002">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Hager</surname><given-names>Kyle R.</given-names></name><xref ref-type="aff" rid="aff002">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Marquis</surname><given-names>Sara R.</given-names></name><xref ref-type="aff" rid="aff001">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Miller</surname><given-names>Samuel I.</given-names></name><xref ref-type="aff" rid="aff002">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Zisman</surname><given-names>Timothy L.</given-names></name><xref ref-type="aff" rid="aff001">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="aff001">
<label>1</label>
<addr-line>Department of Medicine, Division of Gastroenterology, University of Washington, Seattle, Washington, 98195, United States of America</addr-line>
</aff><aff id="aff002">
<label>2</label>
<addr-line>Department of Microbiology, University of Washington, Seattle, Washington, 98195, United States of America</addr-line>
</aff><aff id="aff003">
<label>3</label>
<addr-line>Department of Anatomic Pathology, University of Washington, Seattle, Washington, 98195, United States of America</addr-line>
</aff><contrib-group><contrib contrib-type="editor"><name><surname>Green</surname><given-names>John</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">
<addr-line>University Hospital Llandough, UNITED KINGDOM</addr-line>
</aff><author-notes><fn fn-type="COI-statement" id="coi001"><p><text><SENT sid="1" pm="."><plain>Competing Interests: The authors have declared that no competing interests exist. </plain></SENT>
</text></p></fn><fn fn-type="con" id="contrib001"><p><text><SENT sid="2" pm="."><plain>Conceived and designed the experiments: CJD TLZ SIM. </plain></SENT>
<SENT sid="3" pm="."><plain>Performed the experiments: CJD TLZ KRH SRM. </plain></SENT>
<SENT sid="4" pm="."><plain>Analyzed the data: CJD MW MJB HSH MR. </plain></SENT>
<SENT sid="5" pm="."><plain>Wrote the paper: CJD TLZ MJB SIM. </plain></SENT>
</text></p></fn><corresp id="cor001">* E-mail: <email>cjdamman@uw.edu</email></corresp></author-notes><pub-date pub-type="epub"><day>19</day><month>8</month><year>2015</year></pub-date><pub-date pub-type="collection"><year>2015</year></pub-date><volume>10</volume><issue>8</issue><elocation-id>e0133925</elocation-id><history><date date-type="received"><day>25</day><month>3</month><year>2015</year></date><date date-type="accepted"><day>2</day><month>7</month><year>2015</year></date></history><permissions><copyright-statement>© 2015 Damman et al</copyright-statement><copyright-year>2015</copyright-year><copyright-holder>Damman et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="pone.0133925.pdf"/><abstract><sec id="sec001"><title><text><SENT sid="6" pm="."><plain>Objective </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="7" pm="."><plain>Fecal microbiota transplantation (FMT) is an investigational treatment for diseases thought to involve alterations in the intestinal microbiota including ulcerative colitis (UC). </plain></SENT>
<SENT sid="8" pm="."><plain>Case reports have described therapeutic benefit of FMT in patients with UC, possibly due to changes in the microbiota. </plain></SENT>
<SENT sid="9" pm="."><plain>We measured the degree to which the transplanted microbiota engraft following FMT in patients with UC using a donor similarity index (DSI). </plain></SENT>
</text></SecTag></p></sec><sec id="sec002"><title><text><SENT sid="10" pm="."><plain>Methods </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="11" pm="."><plain>Seven patients with mild to moderate UC (UC disease activity index scores 3–10) received a single colonoscopic administration of FMT. </plain></SENT>
<SENT sid="12" pm="."><plain>Metagenomic sequence data from stool were analyzed using an alignment-free comparison tool, to measure the DSI, and a phylogenetic analysis tool, to characterize taxonomic changes. </plain></SENT>
<SENT sid="13" pm="."><plain>Clinical, endoscopic, histologic, and fecal calprotectin outcome measures were also collected. </plain></SENT>
</text></SecTag></p></sec><sec id="sec003"><title><text><SENT sid="14" pm="."><plain>Results </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="15" pm="."><plain>One of 5 patients from whom sequencing data were available achieved the primary endpoint of 50% donor similarity at week 4; an additional 2 patients achieved 40% donor similarity. </plain></SENT>
<SENT sid="16" pm="."><plain>One patient with 40% donor similarity achieved clinical and histologic remission 1 month after FMT. </plain></SENT>
<SENT sid="17" pm="."><plain>However, these were lost by 2−3 months, and loss correlated with a decrease in DSI. </plain></SENT>
<SENT sid="18" pm="."><plain>The remaining patients did not demonstrate clinical response or remission. </plain></SENT>
<SENT sid="19" pm="."><plain>Histology scores improved in all but 1 patient. </plain></SENT>
<SENT sid="20" pm="."><plain>No patients remained in remission at 3 months after FMT. </plain></SENT>
</text></SecTag></p></sec><sec id="sec004"><title><text><SENT sid="21" pm="."><plain>Conclusions </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="22" pm="."><plain>Following a single colonoscopic fecal transplant, a DSI of 40-50% is achieved in about two-thirds of recipients. </plain></SENT>
<SENT sid="23" pm="."><plain>This level of engraftment correlated with a temporary clinical improvement in only 1/5 patients. </plain></SENT>
<SENT sid="24" pm="."><plain>Larger sample sizes could further validate this method for measuring engraftment, and changes in transplant frequency or method might improve microbiota engraftment and efficacy. </plain></SENT>
</text></SecTag></p></sec><sec id="sec005"><title><text><SENT sid="25" pm="."><plain>Trial Registration </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="26" pm="."><plain>ClinicalTrials.gov <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT01742754?term=NCT01742754">NCT01742754</ext-link> </plain></SENT>
</text></SecTag></p></sec></abstract><funding-group><funding-statement>This work was financially supported by the Broad Foundation (IBD-0038, <ext-link ext-link-type="uri" xlink:href="http://www.ccfa.org/science-and-professionals/broad/">http://www.ccfa.org/science-and-professionals/broad/</ext-link>) and the Kenneth Rainin Foundation (<ext-link ext-link-type="uri" xlink:href="http://krfoundation.org/health/innovator-awards/">http://krfoundation.org/health/innovator-awards/</ext-link>). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><fig-count count="5"/><table-count count="3"/><page-count count="16"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>All relevant data are within the paper and its supporting information files. All sequencing data has been deposited in the National Center for Biotechnology Information (NCBI) Sequence Read Archive (SRA) with BioProject accession number PRJNA285502.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>All relevant data are within the paper and its supporting information files. All sequencing data has been deposited in the National Center for Biotechnology Information (NCBI) Sequence Read Archive (SRA) with BioProject accession number PRJNA285502.</p></notes></front><body><SecTag type="INTRO"><sec sec-type="intro" id="sec006"><title><text><SENT sid="27" pm="."><plain>Introduction </plain></SENT>
</text></title><p><text><SENT sid="28" pm="."><plain>Ulcerative colitis (UC) is a chronic relapsing inflammatory disorder of the colon affecting 0.24% of the population.[1] Current medical treatments for UC include aminosalicylates, thiopurines, corticosteroids, tumor necrosis factor-modulating agents, and other immunosuppressives.[2] These treatments are often limited by actual or perceived risk of side effects, including opportunistic infections, lymphoma, and a lack of response in many patients. </plain></SENT>
<SENT sid="29" pm="."><plain>Indeed, up to twenty-five percent of patients with UC ultimately require colectomy, most commonly for medically refractory disease, highlighting the need for new medical therapies.[3] </plain></SENT>
</text></p><p><text><SENT sid="30" pm="."><plain>In recent years, with the advent of culture-independent sequencing technologies, there have been mounting efforts to understand the role that endogenous gut microbes play in UC and develop new microbial-based therapies. </plain></SENT>
<SENT sid="31" pm="."><plain>Several studies show decreases in normal anaerobic flora (e.g. Clostridial clusters IV and XIVa and Bacteroides ssp.) with reciprocal increases in pathobionts (e.g. Proteobacteria).[4–6] The extent to which alterations in the microbiome are a cause or result of inflammation remains unknown. </plain></SENT>
<SENT sid="32" pm="."><plain>Studies using antibiotics[7] and probiotics[8] for UC have had some success suggesting that alteration of the microbiota may be a successful strategy to achieve disease control in some patients. </plain></SENT>
</text></p><p><text><SENT sid="33" pm="."><plain>Unlike antibiotics that alter the microbiota through further disruption of the normal flora, FMT offers the hope of repleting healthy commensal species and restoring eubiosis. </plain></SENT>
<SENT sid="34" pm="."><plain>Over 300 case reports and a placebo-controlled trial have demonstrated that FMT is safe and efficacious in the treatment of Clostridium difficile-associated diarrhea. </plain></SENT>
<SENT sid="35" pm="."><plain>[9,10] More recently, FMT has been studied in some individuals with UC with modest results.[11,12] Several case reports of FMT have resulted in sustained remission, [13–15] and more recently two randomized controlled trials have shown mixed results.[16,17] The role of microbiota engraftment in possibly inducing remission is unclear. </plain></SENT>
<SENT sid="36" pm="."><plain>We therefore undertook a study to evaluate the effect of a single colonoscopic fecal transplant in mildly to moderately active UC using metagenomic sequencing data to calculate the donor similarity index (DSI) as a measure of engraftment. </plain></SENT>
</text></p></sec></SecTag><SecTag type="METHODS"><sec sec-type="materials|methods" id="sec007"><title><text><SENT sid="37" pm="."><plain>Materials and Methods </plain></SENT>
</text></title><sec id="sec008"><title><text><SENT sid="38" pm="."><plain>Study Oversight </plain></SENT>
</text></title><p><text><SENT sid="39" pm="."><plain>This study was reviewed and initially approved by the University of Washington institutional review board in April 2012 (protocol number 41454). </plain></SENT>
<SENT sid="40" pm="."><plain>Several modifications were made to the protocol prior to enrolling patients and the final protocol was approved October 2012.(S1 Protocol) At the time the study was initiated, fecal microbiota therapy did not fall into the category of a drug or biologic, and given that our primary aim was to evaluate engraftment rather than clinical outcomes, it was unclear whether registration with <ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov/">www.clinicaltrials.gov</ext-link> was necessary. </plain></SENT>
<SENT sid="41" pm="."><plain>Nonetheless, within 30 days of recruiting the first patient, the study was registered at <ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov/">www.clinicaltrials.gov</ext-link> (registration number NCT01742754). </plain></SENT>
<SENT sid="42" pm="."><plain>The authors confirm that all related trials for this intervention will be registered with <ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov/">www.clinicaltrials.gov</ext-link>. </plain></SENT>
<SENT sid="43" pm="."><plain>Written informed consent was obtained from all study subjects including both patients and stool donors. </plain></SENT>
<SENT sid="44" pm="."><plain>Per the IRB submitted protocol we intended to enroll 10 patients and 10 donors. </plain></SENT>
<SENT sid="45" pm="."><plain>Prior to completion of the study, new FDA regulations came out requiring an IND for FMT studies. </plain></SENT>
<SENT sid="46" pm="."><plain>We terminated the study early and have since applied for an IND under a different protocol. </plain></SENT>
</text></p></sec><sec id="sec009"><title><text><SENT sid="47" pm="."><plain>Study Design </plain></SENT>
</text></title><p><text><SENT sid="48" pm="."><plain>This is a prospective, open-label, uncontrolled, single-center pilot study conducted at the University of Washington’s Digestive Disease Center. </plain></SENT>
<SENT sid="49" pm="."><plain>Subjects were enrolled between October 2012 and May of 2013. </plain></SENT>
<SENT sid="50" pm="."><plain>Patients received a single colonoscopic FMT and were followed for up to three months after intervention. </plain></SENT>
<SENT sid="51" pm="."><plain>If a patient developed a flare prior to three months, a last fecal sample was collected at this time. </plain></SENT>
</text></p></sec><sec id="sec010"><title><text><SENT sid="52" pm="."><plain>Patient Selection </plain></SENT>
</text></title><p><text><SENT sid="53" pm="."><plain>Patients were recruited from the University of Washington’s outpatient inflammatory bowel disease clinic and were at least 18 years of age with mildly to moderately active UC as determined by a UC disease activity index (UCDAI) score of 3 to 10.[18] All patients underwent a baseline screening colonoscopy to confirm their diagnosis of UC prior to undergoing FMT. </plain></SENT>
<SENT sid="54" pm="."><plain>Exclusion criteria included antibiotic, biologic, or immunomodulatory therapy (thiopurines or methotrexate) within the last 3 months. </plain></SENT>
<SENT sid="55" pm="."><plain>Patients taking corticosteroid therapy or probiotics required a washout period of 2 weeks. </plain></SENT>
<SENT sid="56" pm="."><plain>With the exception of the above medications, patients were instructed to continue their current medications including 5-aminosalicylates during the duration of the study. </plain></SENT>
<SENT sid="57" pm="."><plain>Patients who tested positive for C. difficile by polymerase chain reaction (PCR) were excluded. </plain></SENT>
</text></p></sec><sec id="sec011"><title><text><SENT sid="58" pm="."><plain>Donor Selection </plain></SENT>
</text></title><p><text><SENT sid="59" pm="."><plain>Donors were chosen by each recipient and had to be at least 18 years of age. </plain></SENT>
<SENT sid="60" pm="."><plain>They were screened for infection risks using a modified American Association of Blood Banks Donor History Questionnaire (S1 Questionnaire). </plain></SENT>
<SENT sid="61" pm="."><plain>Additional exclusion criteria included history of irritable bowel syndrome, inflammatory bowel disease, gastrointestinal malignancy, gastrointestinal polyps, use of antibiotics in the preceding 3 months, immunosuppressive medications, systemic antineoplastic agents, and recent ingestion of a potential allergen. </plain></SENT>
<SENT sid="62" pm="."><plain>Donors were also screened for infectious agents according to the FMT workgroup recommendations.[9] All donors were screened for HIV, HAV, HBV, HCV, and C. difficile. </plain></SENT>
<SENT sid="63" pm="."><plain>Donors who were not intimately involved with the subject were additionally screened for stool enterics, fecal Giardia, Cryptosporidium, Cyclospora, Isospora, ova and parasites, and syphilis. </plain></SENT>
</text></p></sec><sec id="sec012"><title><text><SENT sid="64" pm="."><plain>Donor Stool Preparation and Administration </plain></SENT>
</text></title><p><text><SENT sid="65" pm="."><plain>Prior to FMT, patients underwent a bowel preparation with 4L of GoLYTELY (Braintree Laboratories, Inc. </plain></SENT>
<SENT sid="66" pm="."><plain>Braintree, MA) or an equivalent generic polyethylene glycol and electrolyte solution. </plain></SENT>
<SENT sid="67" pm="."><plain>No antibiotics were administered for the purpose of this study. </plain></SENT>
<SENT sid="68" pm="."><plain>Donor stool was produced fresh on the day of transplant and in all cases was prepared and transplanted within 6 hours. </plain></SENT>
<SENT sid="69" pm="."><plain>In the majority of cases, stool was transplanted within 2 to 3 hours. </plain></SENT>
<SENT sid="70" pm="."><plain>Donor stool was weighed and then diluted with 2-3mL of 0.9% normal saline per gram of stool, depending on the consistency of the donated stool. </plain></SENT>
<SENT sid="71" pm="."><plain>Mixing was performed manually using a tongue depressor. </plain></SENT>
<SENT sid="72" pm="."><plain>The stool mixture was then filtered through gauze and aspirated into 60 cc syringes. </plain></SENT>
<SENT sid="73" pm="."><plain>A total of 175 to 290 cc of this stool mixture was then administered to the terminal ileum and right colon through the working channel of a colonoscope. </plain></SENT>
</text></p></sec><sec id="sec013"><title><text><SENT sid="74" pm="."><plain>Endpoints </plain></SENT>
</text></title><p><text><SENT sid="75" pm="."><plain>The primary endpoint was engraftment of donor stool at 4 weeks post-FMT defined as a DSI of greater than 50% indicating that the microbiota resembled the donor more than the recipient. </plain></SENT>
<SENT sid="76" pm="."><plain>The original endpoint in the IRB submitted protocol was based on 16S rRNA sequencing and UniFrac distances. </plain></SENT>
<SENT sid="77" pm="."><plain>After submission of the protocol and recruitment of patients, but before any sequencing was performed the protocol was amended to perform metagenomic sequencing with alignment-free sequence similarity analysis using Compareads[19] to take advantage of advancements in the field and provide an alternative measure of engraftment. </plain></SENT>
<SENT sid="78" pm="."><plain>Secondary endpoints included a DSI score of greater than 50% at 1 week and 12 weeks post-FMT, clinical response, clinical remission, a decrease in fecal calprotectin, and histologic improvement at week 4. </plain></SENT>
<SENT sid="79" pm="."><plain>We defined response as a decrease in total UCDAI score of 3 or more[18] and remission as a total UCDAI score of 2 or less with no individual subscore greater than 1 at 4 weeks after transplant. </plain></SENT>
<SENT sid="80" pm="."><plain>We also followed a 6-point UCDAI score (fecal blood and stool frequency) to provide non-invasive evaluation of clinical efficacy at time points before and after endoscopy. </plain></SENT>
<SENT sid="81" pm="."><plain>The 6-point partial UCDAI score has been shown to perform as well as the full UCDAI in assessing clinical response in UC.[20] Response in the 6-point UCDAI score was defined as a decrease of 2 or greater. </plain></SENT>
</text></p></sec><sec id="sec014"><title><text><SENT sid="82" pm="."><plain>Sample Collection </plain></SENT>
</text></title><p><text><SENT sid="83" pm="."><plain>Donor stool was collected at about 1 week prior to FMT and again on the day of the transplant. </plain></SENT>
<SENT sid="84" pm="."><plain>Recipient stool was collected at two time points prior to transplant as well as at 1 week, 4 weeks and 12 weeks after transplant or at the time of clinical exacerbation anytime after week 4. </plain></SENT>
<SENT sid="85" pm="."><plain>Baseline samples (prior to FMT) were separated by at least 1 week and in most cases by greater than 1 month. </plain></SENT>
<SENT sid="86" pm="."><plain>Approximately 100–200 mg of stool was collected using a straw core technique[21] and placed into two different cryotubes: one containing 750cc of PowerBead Solution (MoBio, Carlsbad, CA) and another one that was empty. </plain></SENT>
<SENT sid="87" pm="."><plain>These samples were homogenized and frozen at -80°C within 30 minutes of processing. </plain></SENT>
<SENT sid="88" pm="."><plain>Biopsy samples were also collected from the patient during the initial colonoscopy (prior to FMT) and at week 4 during sigmoidoscopy. </plain></SENT>
<SENT sid="89" pm="."><plain>No bowel preparation was prescribed prior to the flexible sigmoidoscopy. </plain></SENT>
<SENT sid="90" pm="."><plain>Biopsy samples were placed in formalin for clinical processing and histological analysis. </plain></SENT>
</text></p></sec><sec id="sec015"><title><text><SENT sid="91" pm="."><plain>DNA Extraction </plain></SENT>
</text></title><p><text><SENT sid="92" pm="."><plain>Bacterial genomic DNA was extracted using the PowerSoil DNA Isolation Kit (MoBio, Carlsbad, CA) with the some modifications. </plain></SENT>
<SENT sid="93" pm="."><plain>One g of 3 mm glass beads (Fisher Scientific, Pittsburgh, PA) was substituted for the garnet beads provided in the kit. </plain></SENT>
<SENT sid="94" pm="."><plain>Two additional incubation steps (65°C for 10 minutes and 95°C for 10 minutes) were inserted after the addition of solution C1 and prior to mechanical disruption (bead beating). </plain></SENT>
</text></p></sec><sec id="sec016"><title><text><SENT sid="95" pm="."><plain>Metagenomic Sequencing </plain></SENT>
</text></title><p><text><SENT sid="96" pm="."><plain>Sequencing was performed on either the Illumina HiSeq 2000 or MiSeq platform. </plain></SENT>
<SENT sid="97" pm="."><plain>Sequencing libraries were constructed from genomic DNA using Illumina’s Nextera technology (Illumina, Inc., San Diego, CA). </plain></SENT>
<SENT sid="98" pm="."><plain>Briefly, DNA preparations were simultaneously fragmented and tagged with adapter oligomers. </plain></SENT>
<SENT sid="99" pm="."><plain>A limited-cycle PCR reaction amplified all tagged fragments and added: 1) index sequences (the dual indexing strategy uses two 8-base indices) to allow demultiplexing of sequence reads for pooled samples, and 2) sequencing primer sequences. </plain></SENT>
<SENT sid="100" pm="."><plain>Following PCR enrichment, libraries were denatured and hybridized via DNA/DNA binding of adaptors to existing features on a glass flow cell compatible with the Illumina sequencers. </plain></SENT>
<SENT sid="101" pm="."><plain>Sequencing was performed using well-established, ultra-high throughput methods. </plain></SENT>
<SENT sid="102" pm="."><plain>The HiSeq2000 produced approximately 200 million pairs of 93 bp reads per lane, and we generated 25–30 million raw read pairs per sample using 7-8-plex pools. </plain></SENT>
<SENT sid="103" pm="."><plain>The single lane of the MiSeq generated 10–20 million raw pairs of 150 bp reads per sample. </plain></SENT>
<SENT sid="104" pm="."><plain>These levels of sequencing provided sufficient depth, post-human and quality filtering as described below, to measure genera represented by greater than 0.2% abundance in the microbiota. </plain></SENT>
<SENT sid="105" pm="."><plain>The metagenomic shotgun sequence was deposited in the National Center for Biotechnology Information (NCBI) Sequence Read Archive (SRA) with BioProject accession number PRJNA285502. </plain></SENT>
</text></p></sec><sec id="sec017"><title><text><SENT sid="106" pm="."><plain>Sequence Quality Control and Analysis </plain></SENT>
</text></title><p><text><SENT sid="107" pm="."><plain>Human DNA sequence was identified and removed using BMTagger[22] with the Hg-19 Homo sapiens reference genome. </plain></SENT>
<SENT sid="108" pm="."><plain>Duplicate reads were marked and removed using EstimateLibraryComplexity, part of the Picard tool package. </plain></SENT>
<SENT sid="109" pm="."><plain>Reads with ambiguous bases were trimmed from each end. </plain></SENT>
<SENT sid="110" pm="."><plain>Reads with Phred quality scores less than 6 over the first 80 (HiSeq) or 120 (MiSeq) bases of each read and reads shorter than 80 (HiSeq) or 120 (MiSeq) bases after trimming were removed. </plain></SENT>
<SENT sid="111" pm="."><plain>Samples with less than 10 million reads following filtering and Human sequence removal were not considered for further analysis. </plain></SENT>
<SENT sid="112" pm="."><plain>We determined relative species abundance from species specific maker genes using MetaPhlAn [23]. </plain></SENT>
</text></p></sec><sec id="sec018"><title><text><SENT sid="113" pm="."><plain>Donor Similarity Index Calculation </plain></SENT>
</text></title><p><text><SENT sid="114" pm="."><plain>The similarity between metagenomic samples was calculated using Compareads[19] with two k-mers of length 30 bases. </plain></SENT>
<SENT sid="115" pm="."><plain>The DSI for the longitudinal samples was calculated as the percent change in recipient to donor similarity relative to baseline similarity to donor. S 0 is the pre-transplant similarity of the recipient to the donor (baseline sample), and S t is the post-transplant similarity of the recipient to the donor at a given time point. </plain></SENT>
</text></p><disp-formula id="pone.0133925.e001"><alternatives><graphic xlink:href="pone.0133925.e001.jpg" id="pone.0133925.e001g" position="anchor" mimetype="image" orientation="portrait"/><mml:math id="M1"><mml:mrow><mml:mi>D</mml:mi><mml:mi>S</mml:mi><mml:mi>I</mml:mi><mml:mo>=</mml:mo><mml:mn>100</mml:mn><mml:mspace width="0.15em"/><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mfrac><mml:mrow><mml:msub><mml:mi>S</mml:mi><mml:mi>t</mml:mi></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mi>S</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mrow><mml:mrow><mml:mn>100</mml:mn><mml:mo>−</mml:mo><mml:msub><mml:mi>S</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mrow></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>,</mml:mo></mml:mrow></mml:math></alternatives><label>(1)</label></disp-formula></sec><sec id="sec019"><title><text><SENT sid="116" pm="."><plain>Fecal Calprotectin </plain></SENT>
</text></title><p><text><SENT sid="117" pm="."><plain>Fecal Calprotectin was measured using the PhiCal Test (Calpro, Oslo, Norway; US distributer Genova Diagnostics, Ashville, NC). </plain></SENT>
</text></p></sec><sec id="sec020"><title><text><SENT sid="118" pm="."><plain>Histology </plain></SENT>
</text></title><p><text><SENT sid="119" pm="."><plain>Biopsy samples targeting the most distal inflamed site within the rectum were placed in formalin, processed and reviewed by a gastroenterology-trained pathologist in a blinded fashion. </plain></SENT>
<SENT sid="120" pm="."><plain>Biopsies were scored based on the following scale: mild(1) = neutrophilic cryptitis, moderate(2) = crypt abscesses, and severe(3) = ulcers. </plain></SENT>
<SENT sid="121" pm="."><plain>A significant clinical response was defined as a change of 2 or more. </plain></SENT>
</text></p></sec><sec id="sec021"><title><text><SENT sid="122" pm="."><plain>Statistical Analysis </plain></SENT>
</text></title><p><text><SENT sid="123" pm="."><plain>All statistical tests were performed with Excel (version 2011; Microsoft, Redmond, WA), GraphPad Prism software (version 6; GraphPad Software, La Jolla, CA), or MedCalc (version 15.4; MedCalc Software bvba, Ostend, Belgium). </plain></SENT>
<SENT sid="124" pm="."><plain>Sample diversity was measured before and after transplant to evaluate for any post transplant increases in diversity using the Shannon-Weiner diversity index described previously[24] in Excel. </plain></SENT>
<SENT sid="125" pm="."><plain>Comparisons in colitis scores and fecal calprotectin levels were made by repeated ANOVA in MedCalc. </plain></SENT>
<SENT sid="126" pm="."><plain>Comparisons of species abundance differences between donors and recipients were performed using a paired 2-tailed TTEST in Excel. </plain></SENT>
<SENT sid="127" pm="."><plain>Statistical correction for multiple testing was performed using the False Discovery Rate (FDR) method. </plain></SENT>
<SENT sid="128" pm="."><plain>P values of less than 0.05 were considered statistically significant. </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="RESULTS"><sec sec-type="results" id="sec022"><title><text><SENT sid="129" pm="."><plain>Results </plain></SENT>
</text></title><sec id="sec023"><title><text><SENT sid="130" pm="."><plain>Patient and Donor Characteristics </plain></SENT>
</text></title><p><text><SENT sid="131" pm="."><plain>There were eight patients enrolled in the study (Fig 1). </plain></SENT>
<SENT sid="132" pm="."><plain>The fourth patient on index colonoscopy was discovered to have Crohn’s disease and was dis-enrolled from the study without further clinical or microbiota analysis. </plain></SENT>
<SENT sid="133" pm="."><plain>The remaining seven patients with endoscopically confirmed UC underwent FMT (Table 1). </plain></SENT>
<SENT sid="134" pm="."><plain>The patients’ median age was 41, median disease duration was 17 years, median baseline UCDAI score was 7.6, and median fecal calprotectin level was 523 μg/g. </plain></SENT>
<SENT sid="135" pm="."><plain>Four patients had left-sided colitis and the remainder had pancolitis. </plain></SENT>
<SENT sid="136" pm="."><plain>Four patients had a history of extra-intestinal manifestations of UC including iritis/uveitis, pyostomatitis vegetans, aphthous stomatitis, and possible sacroiliitis. </plain></SENT>
<SENT sid="137" pm="."><plain>Three patients had a family history of UC. </plain></SENT>
<SENT sid="138" pm="."><plain>Patient three and patient five were mother and son respectively. </plain></SENT>
<SENT sid="139" pm="."><plain>Two patients were active smokers but were smoking at most 1 cigarette per day. </plain></SENT>
<SENT sid="140" pm="."><plain>All patients had previously received treatment with aminosalicylates. </plain></SENT>
<SENT sid="141" pm="."><plain>All donors were male (Table 2). </plain></SENT>
<SENT sid="142" pm="."><plain>The average age of the donors was 41 and the average BMI was 24. </plain></SENT>
<SENT sid="143" pm="."><plain>Four of the 7 donors lived with their respective recipient. </plain></SENT>
<SENT sid="144" pm="."><plain>The donor for patients 3 and 5 was the same individual (donor 3 and donor 3’). </plain></SENT>
</text></p><SecTag type="FIG"><fig id="pone.0133925.g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0133925.g001</object-id><label>Fig 1</label><caption><title><text><SENT sid="145" pm="."><plain>Flow diagram of patient recruitment. </plain></SENT>
</text></title></caption><graphic xlink:href="pone.0133925.g001"/></fig></SecTag><SecTag type="TABLE"><table-wrap id="pone.0133925.t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0133925.t001</object-id><label>Table 1</label><caption><title><text><SENT sid="146" pm="."><plain>Patient Demographics and Disease Characteristics. </plain></SENT>
</text></title></caption><alternatives><graphic id="pone.0133925.t001g" xlink:href="pone.0133925.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1"><text><SENT sid="147" pm="."><plain>Patient </plain></SENT>
</text></th><th align="left" rowspan="1" colspan="1"><text><SENT sid="148" pm="."><plain>Age (years) </plain></SENT>
</text></th><th align="left" rowspan="1" colspan="1"><text><SENT sid="149" pm="."><plain>Sex </plain></SENT>
</text></th><th align="left" rowspan="1" colspan="1"><text><SENT sid="150" pm="."><plain>Disease Duration (years) </plain></SENT>
</text></th><th align="left" rowspan="1" colspan="1"><text><SENT sid="151" pm="."><plain>Baseline UCDAI Score </plain></SENT>
</text></th><th align="left" rowspan="1" colspan="1"><text><SENT sid="152" pm="."><plain>Baseline Calprotectin (μg/g) </plain></SENT>
</text></th><th align="left" rowspan="1" colspan="1"><text><SENT sid="153" pm="."><plain>Disease Extent </plain></SENT>
</text></th><th align="left" rowspan="1" colspan="1"><text><SENT sid="154" pm="."><plain>Extraintestinal Manifestations </plain></SENT>
</text></th><th align="left" rowspan="1" colspan="1"><text><SENT sid="155" pm="."><plain>Family Hx </plain></SENT>
</text></th><th align="left" rowspan="1" colspan="1"><text><SENT sid="156" pm="."><plain>Smoker </plain></SENT>
</text></th><th align="left" rowspan="1" colspan="1"><text><SENT sid="157" pm="."><plain>Prior Therapy </plain></SENT>
</text></th><th align="left" rowspan="1" colspan="1"><text><SENT sid="158" pm="."><plain>Ongoing Therapy </plain></SENT>
</text></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="159" pm="."><plain>1 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="160" pm="."><plain>47 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="161" pm="."><plain>F </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="162" pm="."><plain>26 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="163" pm="."><plain>6 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="164" pm="."><plain>1161 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="165" pm="."><plain>L-sided </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="166" pm="."><plain>iritis/uveitis </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="167" pm="."><plain>None </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="168" pm="."><plain>s/p 13 yrs </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="169" pm="."><plain>5-ASA, Pred, herbal, VSL#3 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="170" pm="."><plain>5-ASA, Chinese herbs, curcumin </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="171" pm="."><plain>2 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="172" pm="."><plain>25 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="173" pm="."><plain>M </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="174" pm="."><plain>6 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="175" pm="."><plain>9 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="176" pm="."><plain>692 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="177" pm="."><plain>Pancolitis </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="178" pm="."><plain>pystomatitis vegetans </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="179" pm="."><plain>None </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="180" pm="."><plain>No </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="181" pm="."><plain>5-ASA, AZA, infliximab </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="182" pm="."><plain>None </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="183" pm="."><plain>3 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="184" pm="."><plain>61 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="185" pm="."><plain>F </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="186" pm="."><plain>40 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="187" pm="."><plain>8 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="188" pm="."><plain>366 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="189" pm="."><plain>Pancolitis </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="190" pm="."><plain>none </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="191" pm="."><plain>Brother and son with UC </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="192" pm="."><plain>1 cig/day </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="193" pm="."><plain>5-ASA, Pred, herbal, VSL#3 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="194" pm="."><plain>5-ASA, boswellia </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="195" pm="."><plain>5 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="196" pm="."><plain>29 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="197" pm="."><plain>M </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="198" pm="."><plain>7 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="199" pm="."><plain>6 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="200" pm="."><plain>280 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="201" pm="."><plain>L-sided </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="202" pm="."><plain>none </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="203" pm="."><plain>Mom with UC </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="204" pm="."><plain>No </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="205" pm="."><plain>5-ASA, VSL#3 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="206" pm="."><plain>5-ASA </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="207" pm="."><plain>6 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="208" pm="."><plain>61 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="209" pm="."><plain>F </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="210" pm="."><plain>22 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="211" pm="."><plain>8 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="212" pm="."><plain>429 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="213" pm="."><plain>L-sided </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="214" pm="."><plain>apthous stomatitis </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="215" pm="."><plain>Mom with UC </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="216" pm="."><plain>No </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="217" pm="."><plain>5-ASA, AZA </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="218" pm="."><plain>None </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="219" pm="."><plain>7 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="220" pm="."><plain>27 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="221" pm="."><plain>F </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="222" pm="."><plain>8 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="223" pm="."><plain>8 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="224" pm="."><plain>209 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="225" pm="."><plain>L-sided </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="226" pm="."><plain>possible sacroiliitis </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="227" pm="."><plain>None </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="228" pm="."><plain>1 cig/week </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="229" pm="."><plain>5-ASA, Entocort, AZA </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="230" pm="."><plain>5-ASA </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="231" pm="."><plain>8 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="232" pm="."><plain>38 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="233" pm="."><plain>F </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="234" pm="."><plain>7 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="235" pm="."><plain>8 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="236" pm="."><plain>ND </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="237" pm="."><plain>Pancolitis </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="238" pm="."><plain>none </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="239" pm="."><plain>None </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="240" pm="."><plain>No </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="241" pm="."><plain>5-ASA, Pred, ABX, AZA, MTX, infliximab, adalimumab </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="242" pm="."><plain>None </plain></SENT>
</text></td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t001fn001"><p><text><SENT sid="243" pm="."><plain>5-ASA = 5-aminosalicylic acid preparations, Pred = prednisone, AZA = azathioprine, ABX = antibiotics, MTX = methotrexate, UCDAI = ulcerative colitis disease activity index </plain></SENT>
</text></p></fn></table-wrap-foot></table-wrap></SecTag><SecTag type="TABLE"><table-wrap id="pone.0133925.t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0133925.t002</object-id><label>Table 2</label><caption><title><text><SENT sid="244" pm="."><plain>Donor Demographics. </plain></SENT>
</text></title></caption><alternatives><graphic id="pone.0133925.t002g" xlink:href="pone.0133925.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1"><text><SENT sid="245" pm="."><plain>Donor </plain></SENT>
</text></th><th align="left" rowspan="1" colspan="1"><text><SENT sid="246" pm="."><plain>Age (years) </plain></SENT>
</text></th><th align="left" rowspan="1" colspan="1"><text><SENT sid="247" pm="."><plain>Sex </plain></SENT>
</text></th><th align="left" rowspan="1" colspan="1"><text><SENT sid="248" pm="."><plain>Height (cm) </plain></SENT>
</text></th><th align="left" rowspan="1" colspan="1"><text><SENT sid="249" pm="."><plain>Weight (kg) </plain></SENT>
</text></th><th align="left" rowspan="1" colspan="1"><text><SENT sid="250" pm="."><plain>BMI (kg/m2) </plain></SENT>
</text></th><th align="left" rowspan="1" colspan="1"><text><SENT sid="251" pm="."><plain>Relationship to Patient </plain></SENT>
</text></th><th align="left" rowspan="1" colspan="1"><text><SENT sid="252" pm="."><plain>Cohabitation </plain></SENT>
</text></th><th align="left" rowspan="1" colspan="1"><text><SENT sid="253" pm="."><plain>PMH </plain></SENT>
</text></th><th align="left" rowspan="1" colspan="1"><text><SENT sid="254" pm="."><plain>Fecal Calprotectin (μg/g) </plain></SENT>
</text></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="255" pm="."><plain>1 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="256" pm="."><plain>41 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="257" pm="."><plain>M </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="258" pm="."><plain>178 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="259" pm="."><plain>75 </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="260" pm="."><plain>23.7 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="261" pm="."><plain>husband </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="262" pm="."><plain>yes </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="263" pm="."><plain>Hypertension </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="264" pm="."><plain>2 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="265" pm="."><plain>2 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="266" pm="."><plain>25 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="267" pm="."><plain>M </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="268" pm="."><plain>191 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="269" pm="."><plain>71 </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="270" pm="."><plain>19.5 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="271" pm="."><plain>roommate </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="272" pm="."><plain>yes </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="273" pm="."><plain>26 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="274" pm="."><plain>3 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="275" pm="."><plain>55 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="276" pm="."><plain>M </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="277" pm="."><plain>185 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="278" pm="."><plain>85 </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="279" pm="."><plain>24.8 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="280" pm="."><plain>husband </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="281" pm="."><plain>yes </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="282" pm="."><plain>16 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="283" pm="."><plain>3' </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="284" pm="."><plain>55 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="285" pm="."><plain>M </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="286" pm="."><plain>185 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="287" pm="."><plain>85 </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="288" pm="."><plain>24.8 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="289" pm="."><plain>father </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="290" pm="."><plain>no </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="291" pm="."><plain>2 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="292" pm="."><plain>6 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="293" pm="."><plain>47 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="294" pm="."><plain>M </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="295" pm="."><plain>183 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="296" pm="."><plain>89 </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="297" pm="."><plain>26.6 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="298" pm="."><plain>brother in law </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="299" pm="."><plain>no </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="300" pm="."><plain>Graves' Disease </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="301" pm="."><plain>17 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="302" pm="."><plain>7 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="303" pm="."><plain>28 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="304" pm="."><plain>M </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="305" pm="."><plain>183 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="306" pm="."><plain>88 </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="307" pm="."><plain>26.6 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="308" pm="."><plain>ex-boyfriend </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="309" pm="."><plain>no </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="310" pm="."><plain>51 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="311" pm="."><plain>8 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="312" pm="."><plain>37 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="313" pm="."><plain>M </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="314" pm="."><plain>175 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="315" pm="."><plain>69 </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="316" pm="."><plain>22.4 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="317" pm="."><plain>husband </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="318" pm="."><plain>yes </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="319" pm="."><plain>  </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="320" pm="."><plain>ND </plain></SENT>
</text></td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t002fn001"><p><text><SENT sid="321" pm="."><plain>BMI = body mass index, PMH = previous medical history </plain></SENT>
</text></p></fn></table-wrap-foot></table-wrap></SecTag></sec><sec id="sec024"><title><text><SENT sid="322" pm="."><plain>FMT Safety </plain></SENT>
</text></title><p><text><SENT sid="323" pm="."><plain>Patients were monitored for adverse events throughout the study. </plain></SENT>
<SENT sid="324" pm="."><plain>Several of the patients reported a mild increase in abdominal cramping and stool output immediately after the transplant. </plain></SENT>
<SENT sid="325" pm="."><plain>These symptoms had resolved by the follow-up appointment at 1 week. </plain></SENT>
<SENT sid="326" pm="."><plain>No patient reported fever. The eighth patient presented with persistent abdominal pain 5 days after the procedure. </plain></SENT>
<SENT sid="328" pm="."><plain>A plain film of the abdomen showed free air suggesting that a micro-perforation had occurred. </plain></SENT>
<SENT sid="329" pm="."><plain>The patient never developed a fever, tachycardia, or leukocytosis and was managed non-operatively and without the need for antibiotics. </plain></SENT>
<SENT sid="330" pm="."><plain>The patient was dis-enrolled from the study without further microbiota analysis. </plain></SENT>
</text></p></sec><sec id="sec025"><title><text><SENT sid="331" pm="."><plain>Clinical, Endoscopic and Histologic Outcomes </plain></SENT>
</text></title><p><text><SENT sid="332" pm="."><plain>One patient had an improvement in UCDAI score from 8 to 2 and was the only patient to achieve clinical remission at 4 weeks after FMT. </plain></SENT>
<SENT sid="333" pm="."><plain>(Fig 2A) This patient’s histology score also decreased from 2 to 0 (absence of inflammation). </plain></SENT>
<SENT sid="334" pm="."><plain>The remaining 5 patients did not achieve clinical response or remission. </plain></SENT>
<SENT sid="335" pm="."><plain>Six-point UCDAI scores showed a trend toward improvement at 1 week (mean change 1.6) and 4 weeks (mean change 0.8) but the change was not statistically significant. </plain></SENT>
<SENT sid="336" pm="."><plain>(Fig 2C) All patients eventually had worsening of their symptoms by 3 months, including the patient who had initially achieved remission. </plain></SENT>
<SENT sid="337" pm="."><plain>Histology scores improved in all but one patient at 4 weeks, but given the small numbers in this study the overall mean change was not statistically significant (Fig 2B). </plain></SENT>
<SENT sid="338" pm="."><plain>Fecal calprotectin initially increased at 1 week after transplant but then decreased to a level below baseline, although these changes were not statistically significant (Fig 2D). </plain></SENT>
</text></p><SecTag type="FIG"><fig id="pone.0133925.g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0133925.g002</object-id><label>Fig 2</label><caption><title><text><SENT sid="339" pm="."><plain>Clinical response to fecal microbiota transplantation. </plain></SENT>
</text></title><p><text><SENT sid="340" pm="."><plain>(A) Ulcerative colitis disease activity index (UCDAI) scores at transplant (TP) and 1 month (1 Mo) after transplant. </plain></SENT>
<SENT sid="341" pm="."><plain>(B) Histology scores at transplant and 1 month after transplant. </plain></SENT>
<SENT sid="342" pm="."><plain>(C) 6-Point UCDAI Scores (Rectal bleeding + Stool Frequency) at baseline (BL), transplant, and after transplant. </plain></SENT>
<SENT sid="343" pm="."><plain>(D) Fecal calprotectin levels at baseline, transplant, and after transplant. </plain></SENT>
<SENT sid="344" pm="."><plain>Vertical lines in figures (C) and (D) represent means with standard deviation. </plain></SENT>
</text></p></caption><graphic xlink:href="pone.0133925.g002"/></fig></SecTag></sec><sec id="sec026"><title><text><SENT sid="345" pm="."><plain>Non-Alignment Based Assessment of Donor Similarity and Stability of FMT </plain></SENT>
</text></title><p><text><SENT sid="346" pm="."><plain>We used Compareads, a non-alignment based method to process the metagenomic data and measure DSI of the transplanted microbiota (Fig 3, Table 3). </plain></SENT>
<SENT sid="347" pm="."><plain>We compared post transplant samples to recipient and donor baseline samples obtained immediately prior to transplant (BL2). </plain></SENT>
<SENT sid="348" pm="."><plain>We then calculated the DSI for each post transplant time point as described in methods. </plain></SENT>
<SENT sid="349" pm="."><plain>For some samples, Compareads analysis could not be performed (CNBP) due to high number of human reads and low numbers of bacterial reads. </plain></SENT>
<SENT sid="350" pm="."><plain>Appropriate controls were used including evaluating baseline change in the microbiota over time prior to transplant. </plain></SENT>
<SENT sid="351" pm="."><plain>Baseline samples are separated by at least one week and in most cases greater than 1 month. </plain></SENT>
<SENT sid="352" pm="."><plain>Pairwise comparisons of recipients to all donors were also performed to show that at 1 week, patients that demonstrated donor similarity showed more similarity to their donor than any other donor. </plain></SENT>
<SENT sid="353" pm="."><plain>(Fig 4) </plain></SENT>
</text></p><SecTag type="FIG"><fig id="pone.0133925.g003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0133925.g003</object-id><label>Fig 3</label><caption><title><text><SENT sid="354" pm="."><plain>Engraftment and Stability of fecal microbiota transplantation. </plain></SENT>
</text></title><p><text><SENT sid="355" pm="."><plain>Recipient similarity to (A) recipient baseline and (B) donor baseline are plotted. </plain></SENT>
<SENT sid="356" pm="."><plain>The (C) DSI sets the second baseline (BL2) similarity to donor to zero and scales the post-transplant similarities. </plain></SENT>
<SENT sid="357" pm="."><plain>One hundred percent indicates perfect engraftment. </plain></SENT>
</text></p></caption><graphic xlink:href="pone.0133925.g003"/></fig></SecTag><SecTag type="FIG"><fig id="pone.0133925.g004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0133925.g004</object-id><label>Fig 4</label><caption><title><text><SENT sid="358" pm="."><plain>Pairwise comparisons of recipient samples. </plain></SENT>
</text></title><p><text><SENT sid="359" pm="."><plain>Pairwise comparison were made between recipient samples before and after transplant (BL 2 and WK 1) to all donor's BL2 samples. </plain></SENT>
<SENT sid="360" pm="."><plain>In patients that demonstrate transplantation, the percent similarity to their donor (dashed lines) increases more than the percent similarity to any other donor (solid lines). </plain></SENT>
<SENT sid="361" pm="."><plain>Please note that recipients 3 and 5 had the same donor with stool collected at different time points (D3 and D3’). </plain></SENT>
</text></p></caption><graphic xlink:href="pone.0133925.g004"/></fig></SecTag><SecTag type="TABLE"><table-wrap id="pone.0133925.t003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0133925.t003</object-id><label>Table 3</label><caption><title><text><SENT sid="362" pm="."><plain>Clinical Outcomes Compared with Engraftment Scores. </plain></SENT>
</text></title></caption><alternatives><graphic id="pone.0133925.t003g" xlink:href="pone.0133925.t003"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1"><text><SENT sid="363" pm="."><plain>Subject </plain></SENT>
</text></th><th align="left" rowspan="1" colspan="1"><text><SENT sid="364" pm="."><plain>Outcomes </plain></SENT>
</text></th><th align="left" rowspan="1" colspan="1"><text><SENT sid="365" pm="."><plain>BL2 </plain></SENT>
</text></th><th align="left" rowspan="1" colspan="1"><text><SENT sid="366" pm="."><plain>TP </plain></SENT>
</text></th><th align="left" rowspan="1" colspan="1"><text><SENT sid="367" pm="."><plain>1 Wk </plain></SENT>
</text></th><th align="left" rowspan="1" colspan="1"><text><SENT sid="368" pm="."><plain>1 Mo </plain></SENT>
</text></th><th align="left" rowspan="1" colspan="1"><text><SENT sid="369" pm="."><plain>2–3 Mo(s) </plain></SENT>
</text></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="370" pm="."><plain>R1 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="371" pm="."><plain>Full UCDAI </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="372" pm="."><plain>  </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="373" pm="."><plain>6 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="374" pm="."><plain>  </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="375" pm="."><plain>5 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="376" pm="."><plain>  </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="377" pm="."><plain>Histology </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="378" pm="."><plain>  </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="379" pm="."><plain>3 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="380" pm="."><plain>  </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="381" pm="."><plain>2 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="382" pm="."><plain>  </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="383" pm="."><plain>6-point UCDAI </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="384" pm="."><plain>5 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="385" pm="."><plain>3 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="386" pm="."><plain>3 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="387" pm="."><plain>2 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="388" pm="."><plain>3 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="389" pm="."><plain>  </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="390" pm="."><plain>Engraftment Score </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="391" pm="."><plain>  </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="392" pm="."><plain>  </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="393" pm="."><plain>3.4 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="394" pm="."><plain>CNBP </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="395" pm="."><plain>13 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="396" pm="."><plain>R2 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="397" pm="."><plain>Full UCDAI </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="398" pm="."><plain>  </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="399" pm="."><plain>9 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="400" pm="."><plain>  </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="401" pm="."><plain>8 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="402" pm="."><plain>  </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="403" pm="."><plain>Histology </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="404" pm="."><plain>  </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="405" pm="."><plain>2 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="406" pm="."><plain>  </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="407" pm="."><plain>1 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="408" pm="."><plain>  </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="409" pm="."><plain>6-point UCDAI </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="410" pm="."><plain>3 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="411" pm="."><plain>5 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="412" pm="."><plain>3 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="413" pm="."><plain>4 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="414" pm="."><plain>4 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="415" pm="."><plain>Engraftment Score </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="416" pm="."><plain>  </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="417" pm="."><plain>  </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="418" pm="."><plain>3.5 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="419" pm="."><plain>CNBP </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="420" pm="."><plain>CNBP </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="421" pm="."><plain>R3 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="422" pm="."><plain>Full UCDAI </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="423" pm="."><plain>  </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="424" pm="."><plain>8 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="425" pm="."><plain>  </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="426" pm="."><plain>2 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="427" pm="."><plain>  </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="428" pm="."><plain>Histology </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="429" pm="."><plain>  </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="430" pm="."><plain>2 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="431" pm="."><plain>  </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="432" pm="."><plain>0 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="433" pm="."><plain>  </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="434" pm="."><plain>6-point UCDAI </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="435" pm="."><plain>4 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="436" pm="."><plain>4 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="437" pm="."><plain>1 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="438" pm="."><plain>1 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="439" pm="."><plain>2 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="440" pm="."><plain>  </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="441" pm="."><plain>Engraftment Score </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="442" pm="."><plain>  </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="443" pm="."><plain>  </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="444" pm="."><plain>43.1 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="445" pm="."><plain>47.9 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="446" pm="."><plain>-4.7 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="447" pm="."><plain>R5 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="448" pm="."><plain>Full UCDAI </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="449" pm="."><plain>  </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="450" pm="."><plain>6 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="451" pm="."><plain>  </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="452" pm="."><plain>6 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="453" pm="."><plain>  </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="454" pm="."><plain>Histology </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="455" pm="."><plain>  </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="456" pm="."><plain>2 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="457" pm="."><plain>  </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="458" pm="."><plain>1 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="459" pm="."><plain>  </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="460" pm="."><plain>6-point UCDAI </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="461" pm="."><plain>3 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="462" pm="."><plain>3 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="463" pm="."><plain>2 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="464" pm="."><plain>2 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="465" pm="."><plain>2 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="466" pm="."><plain>Engraftment Score </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="467" pm="."><plain>  </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="468" pm="."><plain>  </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="469" pm="."><plain>52.9 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="470" pm="."><plain>41.1 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="471" pm="."><plain>19.5 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="472" pm="."><plain>R6 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="473" pm="."><plain>Full UCDAI </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="474" pm="."><plain>  </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="475" pm="."><plain>8 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="476" pm="."><plain>  </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="477" pm="."><plain>6 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="478" pm="."><plain>  </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="479" pm="."><plain>Histology </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="480" pm="."><plain>  </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="481" pm="."><plain>1 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="482" pm="."><plain>  </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="483" pm="."><plain>3 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="484" pm="."><plain>  </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="485" pm="."><plain>6-point UCDAI </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="486" pm="."><plain>4 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="487" pm="."><plain>4 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="488" pm="."><plain>1 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="489" pm="."><plain>5 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="490" pm="."><plain>4 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="491" pm="."><plain>  </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="492" pm="."><plain>Engraftment Score </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="493" pm="."><plain>  </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="494" pm="."><plain>  </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="495" pm="."><plain>43.1 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="496" pm="."><plain>21.1 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="497" pm="."><plain>12.3 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="498" pm="."><plain>R7 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="499" pm="."><plain>Full UCDAI </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="500" pm="."><plain>  </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="501" pm="."><plain>8 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="502" pm="."><plain>  </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="503" pm="."><plain>7 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="504" pm="."><plain>  </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="505" pm="."><plain>Histology </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="506" pm="."><plain>  </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="507" pm="."><plain>2 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="508" pm="."><plain>  </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="509" pm="."><plain>1 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="510" pm="."><plain>  </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="511" pm="."><plain>6-point UCDAI </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="512" pm="."><plain>5 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="513" pm="."><plain>4 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="514" pm="."><plain>4 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="515" pm="."><plain>4 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="516" pm="."><plain>5 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="517" pm="."><plain>  </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="518" pm="."><plain>Engraftment Score </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="519" pm="."><plain>  </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="520" pm="."><plain>  </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="521" pm="."><plain>1.5 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="522" pm="."><plain>18.2 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="523" pm="."><plain>24.9 </plain></SENT>
</text></td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t003fn001"><p><text><SENT sid="524" pm="."><plain>BL2 = baseline 2, TP = transplant, Wk = week, Mo = month, CNBP = could not be performed </plain></SENT>
</text></p></fn></table-wrap-foot></table-wrap></SecTag><p><text><SENT sid="525" pm="."><plain>Two patterns of engraftment were observed: moderate increase in DSI with subsequent decline, and low initial increase in DSI with subsequent rise. </plain></SENT>
<SENT sid="526" pm="."><plain>Recipients 3, 5 and 6 demonstrated the first pattern with moderate increases in DSI’s at 1 week (43%, 53% and 43%) that subsequently decreased by 2–3 months (-4.7, 19.5 and 12.3). </plain></SENT>
<SENT sid="527" pm="."><plain>It is noteworthy that of the patients demonstrating moderate increase in DSI, only patient 3 showed an increase at 1 month. </plain></SENT>
<SENT sid="528" pm="."><plain>This is the only patient that went into remission. </plain></SENT>
<SENT sid="529" pm="."><plain>At 2–3 months she had a flare in her symptoms that correlated with a decrease in her DSI. </plain></SENT>
<SENT sid="530" pm="."><plain>Recipients 1 and 7 demonstrated the second pattern with low DSI’s at 1 week (3% and 2%) that gradually and only slightly increased by 2–3 months (13% and 25%). </plain></SENT>
<SENT sid="531" pm="."><plain>No trend could be determined for patient 2 due to the high number of human reads. </plain></SENT>
</text></p></sec><sec id="sec027"><title><text><SENT sid="532" pm="."><plain>Taxonomic Changes After Transplant </plain></SENT>
</text></title><p><text><SENT sid="533" pm="."><plain>We next aimed to determine how the composition of the microbiota changed after transplant. </plain></SENT>
<SENT sid="534" pm="."><plain>Taxonomic information was mined from the metagenomic data sets using MetaPhlAn and two-hundred and fifteen species were identified across all samples. </plain></SENT>
<SENT sid="535" pm="."><plain>(S1 Table) A Shannon diversity index was calculated for all samples and no significant difference was found between donor and recipient baselines or between pre- and post-transplant samples. </plain></SENT>
<SENT sid="536" pm="."><plain>(Fig 5) </plain></SENT>
</text></p><SecTag type="FIG"><fig id="pone.0133925.g005" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0133925.g005</object-id><label>Fig 5</label><caption><title><text><SENT sid="537" pm="."><plain>Shannon diversity index (SDI) comparisons of samples. </plain></SENT>
</text></title><p><text><SENT sid="538" pm="."><plain>There was no significant difference in baseline recipient and donor diversity. </plain></SENT>
<SENT sid="539" pm="."><plain>(A) There was also no significant difference in diversity at any time point after transplant relative to baseline. </plain></SENT>
<SENT sid="540" pm="."><plain>(B) Vertical lines represent means with standard deviation. </plain></SENT>
</text></p></caption><graphic xlink:href="pone.0133925.g005"/></fig></SecTag><p><text><SENT sid="541" pm="."><plain>Only 19 species demonstrated transplantation in at least one recipient as defined by an increase toward the donor of at least 0.2% from undetectable levels in baseline samples (S1 Table, bolded boxes). </plain></SENT>
<SENT sid="542" pm="."><plain>Some of these species were only transiently transplanted at 1 week, some persisted at all three time points, and some demonstrated transplantation only in later months. </plain></SENT>
<SENT sid="543" pm="."><plain>Most of these species belonged to the phyla Actinobacteria and Bacteroidetes. </plain></SENT>
<SENT sid="544" pm="."><plain>Firmicutes were underrepresented among transplanted species. </plain></SENT>
<SENT sid="545" pm="."><plain>While there were no significant differences in donor and recipient species after correction for multiple testing, three of the transplanted species did show enrichment (significant P value prior to correction for multiple testing) in healthy donors relative to UC patients including Alistipes Shahii, Gordonibacter pamelaeae, and Parabacteroides merdae, (S2 Table). </plain></SENT>
</text></p><p><text><SENT sid="546" pm="."><plain>The majority of post-transplant increases were in species already present in the recipient at baseline. </plain></SENT>
<SENT sid="547" pm="."><plain>Changes of one logarithm or greater were common but most of these represented less than 5% in absolute change.(S3 Table, red numbers) There were 22 species that demonstrated a greater than 5% change in absolute abundance. </plain></SENT>
<SENT sid="548" pm="."><plain>Most notable was an expansion of Prevotella copri in patient 2 (2 logs and 75%). </plain></SENT>
<SENT sid="549" pm="."><plain>There were no trends observed post transplant at higher taxonomic levels. </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="DISCUSS"><sec sec-type="conclusions" id="sec028"><title><text><SENT sid="550" pm="."><plain>Discussion </plain></SENT>
</text></title><p><text><SENT sid="551" pm="."><plain>Our study demonstrates that a single colonoscopic session of FMT without antibiotics did not lead to sustained changes in DSI or clinical improvement in the majority of patients. </plain></SENT>
<SENT sid="552" pm="."><plain>However, one patient did achieve clinical and histologic remission, suggesting that perhaps a subset of patients may engraft with donor stool and may experience clinical improvement. </plain></SENT>
<SENT sid="553" pm="."><plain>We made use of a non-alignment based method for comparing two metagenomic sequences. </plain></SENT>
<SENT sid="554" pm="."><plain>This method avoids any bias associated with mapping reads to taxonomic databases. </plain></SENT>
<SENT sid="555" pm="."><plain>We show an association of DSI with clinical disease course in the one patient in whom transient clinical remission was achieved. </plain></SENT>
<SENT sid="556" pm="."><plain>Two other patients who did not achieve remission at 1 month also demonstrated moderate engraftment (DSI&gt;40%) at 1 week; however, unlike the patient that achieved transient remission they showed a decrease in DSI’s at 1 month. </plain></SENT>
<SENT sid="557" pm="."><plain>While our a priori definition of engraftment had been defined as a DSI of greater than 50% at 1 month, we recognize this definition was chosen arbitrarily and post transplant trends in DSI may be more clinically meaningful. </plain></SENT>
</text></p><p><text><SENT sid="558" pm="."><plain>We also performed taxonomic analysis of the metagenomic sequence. </plain></SENT>
<SENT sid="559" pm="."><plain>After correcting for multiple testing, there were no species that were significantly different between healthy donors and UC recipient. </plain></SENT>
<SENT sid="560" pm="."><plain>Three species (Alistipes Shahii, Gordonibacter pamelaeae, and Parabacteroides merdae) enriched in our healthy subjects (p value &lt;0.05 prior to correcting for multiple testing) demonstrated transplantation in at least one patient. Alistipes Shahii and Parabacteroides merdae belong to the phyla Bacteroidetes and have previously been isolated from appendices of human origin[25] and human stool.[26] Gordonibacter pamelaeae belongs to the phyla Actinobacteria and has previously been isolated from the colon of a patient with Crohn’s disease[27] and from the blood of a patient with rectosigmoid carcinoma.[28] While some of these species have paradoxically been isolated from patients with disease, the relevance of these transplanted species to disease course is unclear and further evaluation of specific strains in patients from our study in models of inflammation could be useful. </plain></SENT>
</text></p><p><text><SENT sid="561" pm="."><plain>Clinically, our results are similar to other small prospective studies of FMT for UC in which response to therapy is minimal and transient.[29–31] These results are different from studies of FMT for C. difficile colitis in which a single FMT session leads to sustained cure rates of greater than 90%.[10] They are also contrary to engraftment studies in CDI and animal models showing that transplanted microbiota are stable for up to a year.[32,33] The lack of sustained response in most patients with UC is consistent with an underlying pathophysiology different from that of C. difficile. </plain></SENT>
<SENT sid="562" pm="."><plain>Rather than being driven by a single pathogen, UC is thought to result from a complex interaction of dysbiotic microbiota with an aberrant immune system. </plain></SENT>
<SENT sid="563" pm="."><plain>The above results suggest that a therapeutic FMT approach to UC will be different from that for C. difficile. </plain></SENT>
</text></p><p><text><SENT sid="564" pm="."><plain>Further studies are warranted to identify the subset of patients with UC who are most likely to respond to FMT, and to determine the optimal FMT administration protocol. </plain></SENT>
<SENT sid="565" pm="."><plain>Pre-transplant bowel lavage and antibiotics, fecal processing method (blended vs. mixed), fecal transmission route (nasoenteric vs. colonoscopic vs. enema), treatment length (single administration vs. serial FMT), and donor selection might all play a role in augmenting FMT engraftment that could allow greater efficacy. </plain></SENT>
</text></p><p><text><SENT sid="566" pm="."><plain>Antibiotics have the potential to remove entrenched dysbiotic species in a process akin to conditioning chemotherapy. </plain></SENT>
<SENT sid="567" pm="."><plain>Antibiotics would ideally be highly selective as they come with the risk of further depleting protective commensals and opening up microbial niches for further dysbiosis. </plain></SENT>
<SENT sid="568" pm="."><plain>A study by Angelberger et al.[30] in which metronidazole was administered did not have improved outcomes, but these results must be interpreted in the context of the more severely affected patient population evaluated (moderate to severe) and the fact that patients had their baseline UC therapy stopped prior to FMT. </plain></SENT>
<SENT sid="569" pm="."><plain>It is also possible that metronidazole lacked the appropriate spectrum of antimicrobial activity. </plain></SENT>
</text></p><p><text><SENT sid="570" pm="."><plain>An alternative to antibiotics is a more robust inoculum of healthy commensals in the form of serial FMT and maintenance therapy. </plain></SENT>
<SENT sid="571" pm="."><plain>This might serve to not only populate the recipient with health promoting bacteria, but also more effectively deplete entrenched inflammatory species via niche exclusion or bacteriocin production in a process akin to graft versus host effects. </plain></SENT>
<SENT sid="572" pm="."><plain>Serial transplantation in UC has been championed by some FMT experts[34] and in a limited form was undertaken by Kunde et al. in a study evaluating serial enemas for 5 days in children. </plain></SENT>
<SENT sid="573" pm="."><plain>[29] This paper had one of the greatest clinical responses to FMT of published prospective studies, but these results must be interpreted in the context of the mild to moderately affected pediatric population that was evaluated. </plain></SENT>
</text></p><p><text><SENT sid="574" pm="."><plain>In regard to donor selection, we did not identify any donor criteria that trended with successful transplantation, although the study was not powered to detect such associations. </plain></SENT>
<SENT sid="575" pm="."><plain>Specifically, we did not find a correlation between baseline microbiota similarity, fecal calprotectin, age, relationship to donor, or cohabitation. </plain></SENT>
<SENT sid="576" pm="."><plain>It is noteworthy that both recipient 3 and 5 had the same donor and both achieved robust DSI increases. </plain></SENT>
</text></p><p><text><SENT sid="577" pm="."><plain>Regarding adverse events, one patient developed a micro-perforation after FMT. </plain></SENT>
<SENT sid="578" pm="."><plain>This was managed non-operatively and without need for hospitalization or antibiotics, as she remained clinically stable and was improving at the time of presentation several days after the procedure. </plain></SENT>
<SENT sid="579" pm="."><plain>Perforation is a known complication of colonoscopy. </plain></SENT>
<SENT sid="580" pm="."><plain>It is unlikely that administration of exogenous stool caused the micro-perforation although it is possible that FMT may have contributed to a greater inflammatory response in an otherwise subclinical event. </plain></SENT>
<SENT sid="581" pm="."><plain>As in other studies, our patients experienced self-limited mild epigastric discomfort and increased stool frequency immediately following the FMT procedure. </plain></SENT>
<SENT sid="582" pm="."><plain>Our patients also showed a paradoxical increase in fecal calprotectin at 1 week that normalized by 1 month. </plain></SENT>
<SENT sid="583" pm="."><plain>This increase was not statistically significant. </plain></SENT>
</text></p><p><text><SENT sid="584" pm="."><plain>There are many limitations to any clinical interpretations of our study. </plain></SENT>
<SENT sid="585" pm="."><plain>It was designed to evaluate engraftment and not as an efficacy trial. </plain></SENT>
<SENT sid="586" pm="."><plain>As such, it is uncontrolled and includes a small number of patients limited to mildly to moderately active disease. </plain></SENT>
<SENT sid="587" pm="."><plain>As a single center study, we cannot exclude investigator bias although we took measures to make endpoints as objective as possible including fecal calprotectin measurement and blinded histology scores. </plain></SENT>
<SENT sid="588" pm="."><plain>While no antibiotics were used in this study prior to FMT, we cannot exclude that the PEG bowel preparation influenced histology scores and microbiota profiles. </plain></SENT>
<SENT sid="589" pm="."><plain>We did not control for diet or fecal transit time and cannot rule out their impact on the intestinal microbiome and disease activity. </plain></SENT>
<SENT sid="590" pm="."><plain>With these limitations in mind, our study suggests that there may be a limited response to FMT in a subset of patients with UC and that improvement in engraftment could improve efficacy. </plain></SENT>
<SENT sid="591" pm="."><plain>Further investigation is warranted to determine the optimal patient and donor selection and FMT administration protocol for UC. </plain></SENT>
</text></p></sec></SecTag><SecTag type="SUPPL"><sec sec-type="supplementary-material" id="sec029"><title><text><SENT sid="592" pm="."><plain>Supporting Information </plain></SENT>
</text></title><supplementary-material content-type="local-data" id="pone.0133925.s001"><label>S1 TREND Statement Checklist</label><caption><title><text><SENT sid="593" pm="."><plain>Trend Statement Checklist. </plain></SENT>
</text></title><p><text><SENT sid="594" pm="."><plain>(PDF) </plain></SENT>
</text></p></caption><media xlink:href="pone.0133925.s001.pdf"><caption><p><text><SENT sid="595" pm="."><plain>Click here for additional data file. </plain></SENT>
</text></p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0133925.s002"><label>S1 Protocol</label><caption><title><text><SENT sid="596" pm="."><plain>Study Protocol. </plain></SENT>
</text></title><p><text><SENT sid="597" pm="."><plain>(PDF) </plain></SENT>
</text></p></caption><media xlink:href="pone.0133925.s002.pdf"><caption><p><text><SENT sid="598" pm="."><plain>Click here for additional data file. </plain></SENT>
</text></p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0133925.s003"><label>S1 Questionnaire</label><caption><title><text><SENT sid="599" pm="."><plain>Full Length Donor History Questionnaire. </plain></SENT>
</text></title><p><text><SENT sid="600" pm="."><plain>(PDF) </plain></SENT>
</text></p></caption><media xlink:href="pone.0133925.s003.pdf"><caption><p><text><SENT sid="601" pm="."><plain>Click here for additional data file. </plain></SENT>
</text></p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0133925.s004"><label>S1 Table</label><caption><title><text><SENT sid="602" pm="."><plain>Heat Map of Relative Species Abundance Acros all Samples. </plain></SENT>
</text></title><p><text><SENT sid="603" pm="."><plain>(PDF) </plain></SENT>
</text></p></caption><media xlink:href="pone.0133925.s004.pdf"><caption><p><text><SENT sid="604" pm="."><plain>Click here for additional data file. </plain></SENT>
</text></p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0133925.s005"><label>S2 Table</label><caption><title><text><SENT sid="605" pm="."><plain>Differences in Percent Abundance of Species at Baseline Between Donor and Recipient. </plain></SENT>
</text></title><p><text><SENT sid="606" pm="."><plain>(PDF) </plain></SENT>
</text></p></caption><media xlink:href="pone.0133925.s005.pdf"><caption><p><text><SENT sid="607" pm="."><plain>Click here for additional data file. </plain></SENT>
</text></p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0133925.s006"><label>S3 Table</label><caption><title><text><SENT sid="608" pm="."><plain>Relative and Absolute Changes in Species. </plain></SENT>
</text></title><p><text><SENT sid="609" pm="."><plain>(PDF) </plain></SENT>
</text></p></caption><media xlink:href="pone.0133925.s006.pdf"><caption><p><text><SENT sid="610" pm="."><plain>Click here for additional data file. </plain></SENT>
</text></p></caption></media></supplementary-material></sec></SecTag></body><back><SecTag type="ACK_FUND"><ack><p><text4fund><text><SENT sid="611" pm="."><plain>Thank you to John Inadomi for departmental support and to Chris Surawicz for help with developing our FMT protocol. </plain></SENT>
<SENT sid="612" pm="."><plain>We would like to thank Ali Johnson and Kelly Crowder for their expertise in executing this clinical trial. </plain></SENT>
<SENT sid="613" pm="."><plain>Thank you to Chelle Wheat for her help with statistical analysis of the data. </plain></SENT>
<SENT sid="614" pm="."><plain>Lastly, we would also like to thank the members of the Miller Lab and Greg Crowther for their illuminating feedback in preparing the manuscript. </plain></SENT>
</text></text4fund></p></ack></SecTag><SecTag type="REF"><ref-list><title>References</title><ref id="pone.0133925.ref001"><text><SENT sid="615" pm="."><plain>1 KappelmanMD, Rifas-ShimanSL, KleinmanK, OllendorfD, BousvarosA, GrandRJ, et al The prevalence and geographic distribution of Crohn’s disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol. 2007;5: 1424–9. 10.1016/j.cgh.2007.07.012 <?supplied-pmid 17904915?>17904915 </plain></SENT>
</text></ref><ref id="pone.0133925.ref002"><text><SENT sid="616" pm="."><plain>2 TalleyNJ, AbreuMT, AchkarJ-P, BernsteinCN, DubinskyMC, HanauerSB, et al An evidence-based systematic review on medical therapies for inflammatory bowel disease. Am J Gastroenterol. </plain></SENT>
<SENT sid="617" pm="."><plain>Nature Publishing Group; 2011;106 Suppl: S2–25; quiz S26. 10.1038/ajg.2011.58 21472012 </plain></SENT>
</text></ref><ref id="pone.0133925.ref003"><text><SENT sid="618" pm="."><plain>3 CimaRR. Timing and indications for colectomy in chronic ulcerative colitis: Surgical consideration. Dig Dis. 2010;28: 501–7. 10.1159/000320409 <?supplied-pmid 20926879?>20926879 </plain></SENT>
</text></ref><ref id="pone.0133925.ref004"><text><SENT sid="619" pm="."><plain>4 NagalingamN a, LynchS V. Role of the microbiota in inflammatory bowel diseases. Inflamm Bowel Dis. 2011; 1–13. 10.1002/ibd.21866  </plain></SENT>
</text></ref><ref id="pone.0133925.ref005"><text><SENT sid="620" pm="."><plain>5 MichailS, DurbinM, TurnerD, GriffithsAM, MackDR, HyamsJ, et al Alterations in the gut microbiome of children with severe ulcerative colitis. Inflamm Bowel Dis. 2012;18: 1799–808. 10.1002/ibd.22860 <?supplied-pmid 22170749?>22170749 </plain></SENT>
</text></ref><ref id="pone.0133925.ref006"><text><SENT sid="621" pm="."><plain>6 Rajilić-StojanovićM, ShanahanF, GuarnerF, de VosWM. Phylogenetic Analysis of Dysbiosis in Ulcerative Colitis During Remission. Inflamm Bowel Dis. 2013;0: 1–8. 10.1097/MIB.0b013e31827fec6d 22532319 </plain></SENT>
</text></ref><ref id="pone.0133925.ref007"><text><SENT sid="622" pm="."><plain>7 KhanKJ, UllmanT a, FordAC, AbreuMT, AbadirA, Abadira, et al Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol. 2011;106: 661–73. 10.1038/ajg.2011.72 <?supplied-pmid 21407187?>21407187 </plain></SENT>
</text></ref><ref id="pone.0133925.ref008"><text><SENT sid="623" pm="."><plain>8 MeijerBJ, DielemanLA. Probiotics in the treatment of human inflammatory bowel diseases: update 2011. J Clin Gastroenterol. 2011;45 Suppl: S139–44. 10.1097/MCG.0b013e31822103f7 <?supplied-pmid 21992953?>21992953 </plain></SENT>
</text></ref><ref id="pone.0133925.ref009"><text><SENT sid="624" pm="."><plain>9 BakkenJS, BorodyT, BrandtLJ, BrillJ V, DemarcoDC, FranzosMA, et al Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol. </plain></SENT>
<SENT sid="625" pm="."><plain>Elsevier Inc.; 2011;9: 1044–9. 10.1016/j.cgh.2011.08.014 <?supplied-pmid 21871249?>21871249 </plain></SENT>
</text></ref><ref id="pone.0133925.ref010"><text><SENT sid="626" pm="."><plain>10 Van NoodE, VriezeA, NieuwdorpM, FuentesS, ZoetendalEG, de VosWM, et al Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013;368: 407–15. 10.1056/NEJMoa1205037 <?supplied-pmid 23323867?>23323867 </plain></SENT>
</text></ref><ref id="pone.0133925.ref011"><text><SENT sid="627" pm="."><plain>11 DammanCJ, MillerSI, SurawiczCM, ZismanTL. The Microbiome and Inflammatory Bowel Disease: Is There a Therapeutic Role for Fecal Microbiota Transplantation? Am J Gastroenterol. 2012;107: 1452–1459. 10.1038/ajg.2012.93 <?supplied-pmid 23034604?>23034604 </plain></SENT>
</text></ref><ref id="pone.0133925.ref012"><text><SENT sid="628" pm="."><plain>12 AndersonJL, EdneyRJ, WhelanK. Systematic review: faecal microbiota transplantation in the management of inflammatory bowel disease. Aliment Pharmacol Ther. 2012;36: 503–16. 10.1111/j.1365-2036.2012.05220.x <?supplied-pmid 22827693?>22827693 </plain></SENT>
</text></ref><ref id="pone.0133925.ref013"><text><SENT sid="629" pm="."><plain>13 BennetJ, BrinkmanM, others. Treatment of ulcerative colitis by implantation of normal colonic flora. Lancet. 1989;1: 164 Available: <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/2563083">http://www.ncbi.nlm.nih.gov/pubmed/2563083</ext-link>  </plain></SENT>
</text></ref><ref id="pone.0133925.ref014"><text><SENT sid="630" pm="."><plain>14 BorodyT, GeorgeL, AndrewsP, BrandlS, NoonanS, ColeP, et al Bowel-flora alteration: a potential cure for inflammatory bowel disease and irritable bowel syndrome? Med J Aust. 1989;150: 604 Available: <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/2783214">http://www.ncbi.nlm.nih.gov/pubmed/2783214</ext-link>  </plain></SENT>
</text></ref><ref id="pone.0133925.ref015"><text><SENT sid="631" pm="."><plain>15 BorodyTJ, WarrenEF, LeisS, SuraceR, AshmanO. Treatment of ulcerative colitis using fecal bacteriotherapy. J Clin Gastroenterol. 2003;37: 42–7. </plain></SENT>
<SENT sid="632" pm="."><plain>Available: <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/12811208">http://www.ncbi.nlm.nih.gov/pubmed/12811208</ext-link> <?supplied-pmid 12811208?>12811208 </plain></SENT>
</text></ref><ref id="pone.0133925.ref016"><text><SENT sid="633" pm="."><plain>16 MoayyediP, SuretteMG, KimPT, LibertucciJ, WolfeM, OnischiC, et al Fecal Microbiota Transplantation Induces Remission in Patients with Active Ulcerative Colitis in a Randomized, Controlled Trial. Gastroenterology. </plain></SENT>
<SENT sid="634" pm="."><plain>Elsevier, Inc; 2015;149: 102–109.e6. 10.1053/j.gastro.2015.04.001 <?supplied-pmid 25857665?>25857665 </plain></SENT>
</text></ref><ref id="pone.0133925.ref017"><text><SENT sid="635" pm="."><plain>17 RossenNG, FuentesS, van der SpekMJ, TijssenJ, HartmanJH a., DuflouA, et al Findings from a Randomized Controlled Trial of Fecal Transplantation for Patients with Ulcerative Colitis. Gastroenterology. 2015; 110–118. 10.1053/j.gastro.2015.03.045 <?supplied-pmid 25836986?>25836986 </plain></SENT>
</text></ref><ref id="pone.0133925.ref018"><text><SENT sid="636" pm="."><plain>18 SchroederKW, TremaineWJ, IlstrupDM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. </plain></SENT>
<SENT sid="637" pm="."><plain>A randomized study. N Engl J Med. 1987;317: 1625–9. 10.1056/NEJM198712243172603 <?supplied-pmid 3317057?>3317057 </plain></SENT>
</text></ref><ref id="pone.0133925.ref019"><text><SENT sid="638" pm="."><plain>19 MailletN, LemaitreC, ChikhiR, LavenierD, PeterlongoP. Compareads: comparing huge metagenomic experiments. BMC Bioinformatics. </plain></SENT>
<SENT sid="639" pm="."><plain>BioMed Central Ltd; 2012;13 Suppl 1: S10 10.1186/1471-2105-13-S19-S10 <?supplied-pmid 23282463?>23282463 </plain></SENT>
</text></ref><ref id="pone.0133925.ref020"><text><SENT sid="640" pm="."><plain>20 LewisJD, ChuaiS, NesselL, LichtensteinGR, AberraFN, EllenbergJH. Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis. Inflamm Bowel Dis. 2008;14: 1660–6. 10.1002/ibd.20520 <?supplied-pmid 18623174?>18623174 </plain></SENT>
</text></ref><ref id="pone.0133925.ref021"><text><SENT sid="641" pm="."><plain>21 SwidsinskiA, Loening-BauckeV, VerstraelenH, OsowskaS, DoerffelY. Biostructure of fecal microbiota in healthy subjects and patients with chronic idiopathic diarrhea. Gastroenterology. 2008;135: 568–79. 10.1053/j.gastro.2008.04.017 <?supplied-pmid 18570896?>18570896 </plain></SENT>
</text></ref><ref id="pone.0133925.ref022"><text><SENT sid="642" pm="."><plain>22Rotmistrovsky KAR. </plain></SENT>
<SENT sid="643" pm="."><plain>BMTagger: Best Match Tagger for removing human reads from metagenomics datasets. </plain></SENT>
<SENT sid="644" pm="."><plain>Unpublished. </plain></SENT>
<SENT sid="645" pm="."><plain>2011; </plain></SENT>
</text></ref><ref id="pone.0133925.ref023"><text><SENT sid="646" pm="."><plain>23 SegataN, WaldronL, BallariniA, NarasimhanV, JoussonO, HuttenhowerC. Metagenomic microbial community profiling using unique clade-specific marker genes. Nat Methods. 2012;9: 811–4. 10.1038/nmeth.2066 <?supplied-pmid 22688413?>22688413 </plain></SENT>
</text></ref><ref id="pone.0133925.ref024"><text><SENT sid="647" pm="."><plain>24 ShannonCE. A mathematical theory of communication. Bell Syst Tech J. 1948;27: 379–423; 623–656. </plain></SENT>
</text></ref><ref id="pone.0133925.ref025"><text><SENT sid="648" pm="."><plain>25 SongY, KönönenE, RautioM, LiuC, BrykA, EerolaE, et al Alistipes onderdonkii sp. nov. and Alistipes shahii sp. nov., of human origin. Int J Syst Evol Microbiol. 2006;56: 1985–90. 10.1099/ijs.0.64318-0 <?supplied-pmid 16902041?>16902041 </plain></SENT>
</text></ref><ref id="pone.0133925.ref026"><text><SENT sid="649" pm="."><plain>26Feces H, Johnson JL, Moore WEC, Moore LVH. </plain></SENT>
<SENT sid="650" pm="."><plain>Bacteroides caccae. </plain></SENT>
<SENT sid="651" pm="."><plain>1986; 499–501. </plain></SENT>
</text></ref><ref id="pone.0133925.ref027"><text><SENT sid="652" pm="."><plain>27 WürdemannD, TindallBJ, PukallR, LünsdorfH, StrömplC, NamuthT, et al Gordonibacter pamelaeae gen. nov., sp. nov., a new member of the Coriobacteriaceae isolated from a patient with Crohn’s disease, and reclassification of Eggerthella hongkongensis Lau et al. 2006 as Paraeggerthella hongkongensis gen. nov., comb. nov. Int J Syst Evol Microbiol. 2009;59: 1405–15. 10.1099/ijs.0.005900-0 <?supplied-pmid 19502325?>19502325 </plain></SENT>
</text></ref><ref id="pone.0133925.ref028"><text><SENT sid="654" pm="."><plain>28 WooPCY, TengJLL, LamKKM, TseCWS, LeungK-W, LeungAWS, et al First report of Gordonibacter pamelaeae bacteremia. J Clin Microbiol. 2010;48: 319–22. 10.1128/JCM.01459-09 <?supplied-pmid 19923481?>19923481 </plain></SENT>
</text></ref><ref id="pone.0133925.ref029"><text><SENT sid="655" pm="."><plain>29 KundeS, PhamA, BonczykS, CrumbT, DubaM, ConradH, et al Safety, tolerability, and clinical response after fecal transplantation in children and young adults with ulcerative colitis. J Pediatr Gastroenterol Nutr. 2013;56: 597–601. 10.1097/MPG.0b013e318292fa0d <?supplied-pmid 23542823?>23542823 </plain></SENT>
</text></ref><ref id="pone.0133925.ref030"><text><SENT sid="656" pm="."><plain>30 AngelbergerS, ReinischW, MakristathisA, LichtenbergerC, DejacoC, PapayP, et al Temporal bacterial community dynamics vary among ulcerative colitis patients after fecal microbiota transplantation. Am J Gastroenterol. 2013;108: 1620–30. 10.1038/ajg.2013.257 <?supplied-pmid 24060759?>24060759 </plain></SENT>
</text></ref><ref id="pone.0133925.ref031"><text><SENT sid="657" pm="."><plain>31 KumpPK, GröchenigH-P, LacknerS, TrajanoskiS, ReichtG, HoffmannKM, et al Alteration of Intestinal Dysbiosis by Fecal Microbiota Transplantation Does not Induce Remission in Patients with Chronic Active Ulcerative Colitis. Inflamm Bowel Dis. 2013;19: 2155–2165. 10.1097/MIB.0b013e31829ea325 <?supplied-pmid 23899544?>23899544 </plain></SENT>
</text></ref><ref id="pone.0133925.ref032"><text><SENT sid="658" pm="."><plain>32 AlpertC, SczesnyS, GruhlB, BlautM. Long-term stability of the human gut microbiota in two different rat strains. Curr Issues Mol Biol. 2008;10: 17–24. </plain></SENT>
<SENT sid="659" pm="."><plain>Available: <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/18525103">http://www.ncbi.nlm.nih.gov/pubmed/18525103</ext-link> <?supplied-pmid 18525103?>18525103 </plain></SENT>
</text></ref><ref id="pone.0133925.ref033"><text><SENT sid="660" pm="."><plain>33 KhorutsA, DicksvedJ, JanssonJK, SadowskyMJ. Changes in the composition of the human fecal microbiome after bacteriotherapy for recurrent Clostridium difficile-associated diarrhea. J Clin Gastroenterol. 2010;44: 354–60. 10.1097/MCG.0b013e3181c87e02 <?supplied-pmid 20048681?>20048681 </plain></SENT>
</text></ref><ref id="pone.0133925.ref034"><text><SENT sid="661" pm="."><plain>34 BorodyTJ, KhorutsA. Fecal microbiota transplantation and emerging applications. Nat Rev Gastroenterol Hepatol. </plain></SENT>
<SENT sid="662" pm="."><plain>Nature Publishing Group; 2012;9: 88–96. 10.1038/nrgastro.2011.244  </plain></SENT>
</text></ref></ref-list></SecTag></back></article>
